Japan· JP-3399409G2024
フィルグラスチム（遺伝子組換え）［フィルグラスチム後続２］
A medicinal product containing フィルグラスチム（遺伝子組換え）［フィルグラスチム後続２］, registered in Japan by 日本化薬, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- フィルグラスチム（遺伝子組換え）［フィルグラスチム後続２］
- Manufacturer
- 日本化薬
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
フィルグラスチム（遺伝子組換え）［フィルグラスチム後続２］ in 18 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaACCOFILAccord Healthcare S.L.U., Barcelona
- FinlandAccofilAccord Healthcare S.L.U.
- United StatesFILKRIAccord BioPharma Inc.,
- SpainACCOFIL 12 MU/0,2 ML SOLUCION INYECTABLE Y PARA PERFUSION EN JERINGA PRECARGADAAccord Healthcare S.L.U.
- BelgiumAccofil 12 10*6 U/0.2 mlAccord Healthcare
- PolandAccofilAccord Healthcare S.L.U.
- IrelandAccofil 30 MU/0.5 ml solution for injection/infusion in pre-filled syringeAccord Healthcare S.L.U.
- FranceACCOFIL 12 MU/0,2 ml, solution injectable ou pour perfusion en seringue préremplieACCORD HEALTHCARE (ESPAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Belgium · Neupogen
- Germany · Neupogen
- Spain · Neupogen
- France · Neupogen
- United Kingdom (Northern Ireland) · Neupogen, Neupogen Singleject
- Ireland · Neupogen, Neupogen Singleject
- Iceland · Accofil, Filgrastim Hexal
- Italy · Granulokine
- Liechtenstein · Accofil, Filgrastim Hexal
- Luxembourg · Neupogen
- Netherlands · Neupogen, Neupogen Singleject
- Norway · Accofil, Filgrastim Hexal
- Poland · Neupogen
- Sweden · Neupogen
- Slovenia · Neupogen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bc88d34c-1ad2-451d-b50e-f4f894c61a5b GET /v1/drugs/bc88d34c-1ad2-451d-b50e-f4f894c61a5b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１５０μｇ０．６ｍＬ１筒",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3399409G2024",
"category": "注射薬",
"price_yen": 3340,
"generic_name": "フィルグラスチム（遺伝子組換え）［フィルグラスチム後続２］",
"product_name_jp": null,
"therapeutic_class": "3399",
"transitional_expiry": null
}See everything about フィルグラスチム（遺伝子組換え）［フィルグラスチム後続２］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.